R
Richard E. Champlin
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1500
Citations - 73470
Richard E. Champlin is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 138, co-authored 1402 publications receiving 66917 citations.
Papers
More filters
Journal Article
Pharmacokinetics, dosimetry and toxicity of holmium-166-DOTMP for bone marrow ablation in multiple myeloma.
J. E. Bayouth,Daniel J. Macey,Leela P. Kasi,Garlich Joseph R,Mcmillan Kenneth,Meletios A. Dimopoulos,Richard E. Champlin +6 more
TL;DR: All patients demonstrated severe bone marrow toxicity with a white blood cell count < 1,000 cells/ microliters, two patients exhibited marrow ablation (WBC count < 100 cells/microliters), and no other toxicity was observed in any of the patients.
Journal ArticleDOI
Tacrolimus-associated posterior reversible encephalopathy syndrome in hematopoietic allogeneic stem cell transplantation.
Aimee E. Hammerstrom,Joshua Howell,Alison M. Gulbis,Gabriela Rondon,Richard E. Champlin,Uday R. Popat +5 more
TL;DR: A retrospective review of patients receiving tacrolimus for prevention of graft versus host disease after allogeneic SCT who developed PRES from September 2008 to July 2011 found it was associated with high blood pressure and adequate blood pressure control should be part of its management.
Journal ArticleDOI
PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies
M.H. Qazilbash,Eric D. Wieder,Peter F. Thall,Xiaohong I. Wang,R. Rios,S. Lu,S. Kanodia,K. E. Ruisaard,Sergio Giralt,Eli Estey,Jorge E. Cortes,Krishna V. Komanduri,Karen Clise-Dwyer,Gheath Alatrash,Qing Ma,Richard E. Champlin,Jeffrey J. Molldrem +16 more
TL;DR: In conclusion, PR1 peptide vaccine induces specific immunity that correlates with clinical responses, including molecular remission, in AML, CML and MDS patients.
Journal ArticleDOI
Allogeneic blood stem cell transplantation in advanced hematologic cancers
Donna Przepiorka,Paolo Anderlini,Cindy Ippoliti,Issa F. Khouri,T. Fietz,Peter F. Thall,Rakesh Mehra,Sergio Giralt,James Gajewski,Albert B. Deisseroth,Karen R. Cleary,Richard E. Champlin,K. Van Besien,Borje S. Andersson,Martin Korbling +14 more
TL;DR: Blood stem cell recipients had the least regimen-related toxicity, fewest early deaths and earliest discharge when compared to bone marrow transplants, and use of blood stem cell grafts has substantial advantages over marrow grafts.
Journal ArticleDOI
Long-term results favor allogeneic over autologous hematopoietic stem cell transplantation in patients with refractory or recurrent indolent non-Hodgkin’s lymphoma
Chitra Hosing,Rima M. Saliba,Patricia J. McLaughlin,Borje S. Andersson,Maria Alma Rodriguez,Luis Fayad,Fernando Cabanillas,Richard E. Champlin,Issa F. Khouri +8 more
TL;DR: Patients who undergo HDT with allogeneic SCT for refractory or recurrent indolent NHL have lower relapse rates but higher treatment-related mortality rates than patients who undergo autologous SCT.